Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 3/20 | 0.36 |
| ▸ | RAB9A | P51151 | 3/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | PLK4 | O00444 | 1/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.36 |
| ▸ | AURKA | O14965 | 1/20 | 0.36 |
| ▸ | CHUK | O15111 | 1/20 | 0.36 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
| ▸ | PAK4 | O96013 | 1/20 | 0.36 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.36 |
| ▸ | CDK1 | P06493 | 1/20 | 0.36 |
| ▸ | PIM1 | P11309 | 1/20 | 0.36 |
| ▸ | PRKACA | P17612 | 1/20 | 0.36 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.36 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10198582 | 0.98 | PLK4 (0.37) | PTGS1MAPK14NPC1RAB9AMAPK1 | |
| SCHEMBL85723 | 0.90 | PLK4 (0.38) | MAPK14NPC1RAB9AMAPK1ALDH1A1 | |
| SCHEMBL18116453 | 0.90 | PLK4 (0.38) | MAPK14NPC1RAB9AMAPK1ALDH1A1 | |
| SCHEMBL17943881 | 0.87 | PLK4 (0.36) | MAPK14NPC1RAB9AMAPK1ALDH1A1 | |
| SCHEMBL16605514 | 0.87 | PTGS1 (0.38) | PTGS1MAPK14NPC1RAB9AMAPK1 | |
| SCHEMBL11932050 | 0.86 | HDAC1 (0.40) | PTGS1MAPK14NPC1RAB9AMAPK1 | |
| SCHEMBL85722 | 0.86 | PTGS1 (0.44) | PTGS1NPC1RAB9AMAPK1ALDH1A1 | |
| SCHEMBL86141 | 0.86 | NPC1 (0.36) | NPC1RAB9AMAPK1ALDH1A1CASP3 | |
| SCHEMBL85873 | 0.86 | HDAC3 (0.46) | HDAC8HDAC6HDAC3HDAC1 | |
| SCHEMBL10198578 | 0.84 | NPC1 (0.35) | NPC1RAB9AALDH1A1CASP3HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10603294-B2 | Compounds for use in treatment of mucositis | INNOVATION PHARMACEUTICALS INC. (US) | 2020-03-31 | — | — | US | disclosed |
| US-20190282521-A1 | Compounds For Use In Treatment Of Mucositis | POLYMEDIX, INC. | 2019-09-19 | — | — | US | disclosed |
| US-10206894-B2 | Compounds for use in treatment of mucositis | INNOVATION PHARMACEUTICALS INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-20180064664-A1 | Compounds For Use In Treatment of Mucositis | POLYMEDIX, INC. | 2018-03-08 | — | — | US | disclosed |
| US-9795575-B2 | Compounds for use in treatment of mucositis | INNOVATION PHARMACEUTICALS INC. (US) | 2017-10-24 | — | — | US | disclosed |
| EP-2709619-B1 | COMPOUNDS FOR USE IN TREATMENT OF MUCOSITIS | CELLCEUTIX CORP (US) | 2017-10-11 | — | — | EP | disclosed |
| US-20170224640-A1 | Compounds For Use In Treatment Of Mucositis | INNOVATION PHARMACEUTICALS INC. | 2017-08-10 | — | — | US | disclosed |
| US-9457027-B2 | Compounds for use in treatment of mucostis | CELLCEUTIX CORPORATION (US) | 2016-10-04 | — | — | US | disclosed |
| US-20160213668-A1 | Compounds for use in Treatment of Mucostis | INNOVATION PHARMACEUTICALS INC. | 2016-07-28 | — | — | US | disclosed |
| US-20160151314-A1 | Facially Amphiphilic Polymers and Oligomers and Uses Thereof | NATIONAL SCIENCE FOUNDATION | 2016-06-02 | — | — | US | disclosed |
| US-20100298344-A1 | Polycationic Compounds And Uses Thereof | POLYMEDIX, INC. | 2010-11-25 | — | — | US | disclosed |
| US-20100298344-A1 | Polycationic Compounds And Uses Thereof | POLYMEDIX, INC. | 2010-11-25 | — | — | US | disclosed |
| US-7745662-B2 | Polycationic compounds and uses thereof | POLYMEDIX, INC. (US) | 2010-06-29 | — | — | US | disclosed |
| US-7745662-B2 | Polycationic compounds and uses thereof | POLYMEDIX, INC. (US) | 2010-06-29 | — | — | US | disclosed |
| US-20090239811-A1 | POLYCATIONIC COMPOUNDS AND USES THEREOF | POLYMEDIX, INC. (US) | 2009-09-24 | — | — | US | disclosed |
| US-20090239811-A1 | POLYCATIONIC COMPOUNDS AND USES THEREOF | POLYMEDIX, INC. (US) | 2009-09-24 | — | — | US | disclosed |
| US-7553876-B2 | Polycationic compounds and uses thereof | POLYMEDIX, INC. (US) | 2009-06-30 | — | — | US | disclosed |
| US-7553876-B2 | Polycationic compounds and uses thereof | POLYMEDIX, INC. (US) | 2009-06-30 | — | — | US | disclosed |
| US-20080176807-A1 | Facially amphiphilic polymers and oligomers and uses thereof | MIDCAP FINANCIAL SBIC, LP, AS ADMINISTRATIVE AGENT | 2008-07-24 | — | — | US | disclosed |
| US-20080176807-A1 | Facially amphiphilic polymers and oligomers and uses thereof | MIDCAP FINANCIAL SBIC, LP, AS ADMINISTRATIVE AGENT | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176807-A1 | Facially amphiphilic polymers and oligomers and uses thereof | TLR3, ABHD16A, ANTXR2 | PTGS1 3230/4885MAPK14 3508/4885NPC1 1343/4885 |
| US-20170224640-A1 | Compounds For Use In Treatment Of Mucositis | MUC1, FUT6, MMP8 | PTGS1 202/4885MAPK14 4340/4885NPC1 571/4885 |
| US-10603294-B2 | Compounds for use in treatment of mucositis | MUC1, FUT6, MMP8 | PTGS1 202/4885MAPK14 4340/4885NPC1 571/4885 |
| US-20160151314-A1 | Facially Amphiphilic Polymers and Oligomers and Uses Thereof | TLR3, ABHD16A, ANTXR2 | PTGS1 3230/4885MAPK14 3508/4885NPC1 1343/4885 |
| US-20100298344-A1 | Polycationic Compounds And Uses Thereof | VEGFA, VHL, PGF | PTGS1 37/4885MAPK14 2309/4885NPC1 1800/4885 |
| US-10206894-B2 | Compounds for use in treatment of mucositis | MUC1, FUT6, SI | PTGS1 194/4885MAPK14 3914/4885NPC1 791/4885 |
| US-20090239811-A1 | POLYCATIONIC COMPOUNDS AND USES THEREOF | VEGFA, VHL, PGF | PTGS1 37/4885MAPK14 2309/4885NPC1 1800/4885 |
| US-20190282521-A1 | Compounds For Use In Treatment Of Mucositis | MUC1, FUT6, MMP8 | PTGS1 202/4885MAPK14 4340/4885NPC1 571/4885 |
| US-20180064664-A1 | Compounds For Use In Treatment of Mucositis | MUC1, FUT6, SI | PTGS1 194/4885MAPK14 3914/4885NPC1 791/4885 |
| US-20160213668-A1 | Compounds for use in Treatment of Mucostis | MUC1, SOST, ALG1 | PTGS1 186/4885MAPK14 4121/4885NPC1 590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.